Biocon Biologics Ltd, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).

Biocon Biologics’ strong R&D and manufacturing capabilities have enabled the Company to offer affordable biologics such as bTrastuzumab and bPegfilgrastim to cancer patients in developed markets like the European Union (EU) and the United States (US). Biocon Biologics will initially supply bTrastuzumab and bPegfilgrastim and will expand the arrangement to include other biosimilars.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics said: “The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through cost-effective alternatives to expensive reference biologics.”

Dr Christiane Hamacher, CEO, Biocon Biologics said: “We are committed to reducing the high cost of cancer care for healthcare systems through our biosimilars and are pleased to address the needs of patients in Africa and Asia through the Cancer Access Partnership (CAP).”

Dr Ian Barton, CEO, CHAI, stated: “Expanding the Cancer Access Partnership to include high-quality biologics from Biocon takes us another step closer to ensuring that cancer patients have access to the quality medications that they need at an affordable price, no matter where they live.”